The development of rheumatology at the stage of formation of a new technological paradigm
https://doi.org/10.14412/1995-4484-2019-490-495
Abstract
Using rheumatology as an example, the paper considers current trends in the development of medical science in the 21st century. It is emphasized that biochemistry, genetics, and molecular biology are becoming the central research priority site attracting to clinical medicine and rheumatology, neuroscience (including cognitive and computational neurobiology, neuroinformatics), and psychology. Modern rheumatology effectively adapts current scientific achievements, which contributes to the significant progress of fundamental and clinical medicine. Deciphering the key immune mechanisms of the pathogenesis of immune-mediated inflammatory rheumatic diseases (IIRD) has allowed biotechnology techniques to be used to design fundamentally new drugs, such as biological agents, small molecules that are able to selectively affect certain pathogenetic constituents and to minimize the overall functioning of the immune system. This could substantially enhance the efficiency of treatment for IIRDs, by achieving a long-term stable remission in many patients and contributed to a significant expansion of ideas on human pathology. It is assumed that most promising studies of pharmacotherapy for IIRDs towards personalized medicine will be based on postgenomic technologies, including proteomics, transcriptomics, metabolomics, epigenomics, as well as the integrated use of digital methods.
About the Author
T. V. Beketova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Tatiana Beketova.
34A, Kashirskoe Shosse, Moscow 115522.
References
1. Grinin LE, Korotaev AV, Bondarenko VM, eds. N. D. Kondrat'ev: krizisy i prognozy v svete teorii dlinnykh voln. Vzglyad iz sovremennosti [N.D. Kondratiev: crises and forecasts in the light of the theory of long waves. A look from the present]. Moscow: Moskovskaya redaktsiya izdatel'stva «Uchitel'»; 2017. 384 p. ISBN: 978-5-7057-5167-9 (In Russ.).
2. Lynch Z. Neurotechnology and society (2010-2060). Ann N Y Acad Sci. 2004 May;1013:229-33. doi: 10.1196/annals.1305.016
3. Bainbridge MS, Roco MC. Managing Nano-Bio-Info-Cogno Innovations: Converging Technologies in Society. New York, NY: Springer; 2005.
4. Koval'chuk MV. The convergence of science and technology –a breakthrough into the future. Rossiyskie Nanotekhnologii. 2011;6(1-2). Available from: http://www.nrcki.ru/files/nbik01.pdf (In Russ.).
5. Nefiodow L, Nefiodow S. The Sixth Kondratieff. The New Long Wave of the World. 2017, Sankt-Augustin, Germany. Р. 252. ISBN-10: 1545485143 ISBN-13: 978-1545485149
6. Nasonov EL. Achievements in rheumatology in the XXI century. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(2):133-40 (In Russ.). doi: 10.14412/1995-4484-2014-133-140
7. Rheumatoid Arthritis Drugs / Therapeutics Market Size Analysis Report By Molecule Type (Biopharmaceuticals (Biologics, Biosimilars), Pharmaceuticals), By Sales Channel (Prescription, OTC), And Segment Forecasts, 2018-2025. Available from: https://www.grandviewresearch.com/industry-analysis/rheumatoid-arthritis-therapeutics-market
8. Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: the problems of remission and therapy resistance. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):263-71 (In Russ.). doi: 10.14412/1995-4484-2018-263-271
9. Belov BS, Naumtseva MS, Tarasova GM, Bukhanova DV. Targeted therapy and infections in rheumatic diseases. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2016;10(4):4-15 (In Russ.). doi: 10.14412/1996-7012-2016-4-4-15
10. Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19 (In Russ.). doi: 10.14412/1995-4484-2017-409-419
11. Nasonov EL. New possibilities of pharmacotherapy for immunoinflammatory rheumatic diseases: A focus on inhibitors of interleukin-17. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(1):68-86 (In Russ.). doi: 10.14412/1995-4484-2017-68-86
12. Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(6): 590-9 (In Russ.). doi: 10.14412/1995-4484-2017-590-599
13. Nasonov EL, Lila AM. The use of rituximab and other anti-B cell preparations for immunoinflammatory rheumatic diseases. Klinicheskaya Farmakologiya i Terapiya. 2019;28(1):7-17 (In Russ.). doi: 10.32756/0869-5490-2019-1-7-17.
14. Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16 (In Russ.). doi: 10.14412/1995-4484-2019-8-16
15. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78. doi: 10.1038/nrd.2017.267
16. Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs. 2019 Feb;33(1):15-32. doi: 10.1007/s40259-019-00333-w
17. Beketova TV. Promising directions for the treatment of systemic vasculitis: focus on avakopan, an oral selective inhibitor of C5a receptor. Klinicheskaya Farmakologiya i Terapiya. 2019;28(1):75-9 (In Russ.). doi: 10.32756/0869-5490-2019-1-75-79
18. Gunn GR 3rd, Sealey DC, Jamali F, et al. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals. Clin Exp Immunol. 2016 May;184(2):137-46. doi: 10.1111/cei.12742
19. Nasonov EL. Biosimilars in rheumatology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(6):628-40 (In Russ.). doi: 10.14412/1995-4484-2016-628-640
20. Smolen JS, Goncalves J, Quinn M, et al. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5(1):e000900. doi: 10.1136/rmdopen-2019-000900
21. Popkova TV, Novikova DS, Nasonov EL. Cardiovascular diseases in rheumatoid arthritis: Latest data. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(2):122-8 (In Russ.). doi: 10.14412/1995-4484-2016-122-128
22. Lisitsyna TA, Veltishchev DYu. Mental disorders in patients with rheumatic diseases: Diagnosis and treatment. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):512-21 (In Russ.). doi: 10.14412/1995-4484-2015-512-521
23. Han X, Yang D, Yang C, et al. Carbon Fiber Reinforced PEEK Composites based on 3D-printing technology for orthopedic and dental applications. J Clin Med. 2019 Feb 12;8(2). pii: E240. doi: 10.3390/jcm8020240
24. Liow MHL, Chin PL, Pang HN, et al. THINK surgical TSolution-One® (Robodoc) total knee arthroplasty. SICOT J. 2017;3:63. doi: 10.1051/sicotj/2017052
25. Khramov AE, Makarov MA, Makarov SA, et al. Local complications of hip and knee joint replacement in patients with rheumatoid arthritis and osteoarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):549-54 (In Russ.). doi: 10.14412/1995-4484-2017-549-554
26. Gordeev AV, Galushko EA, Nasonov EL. The concept of multimorbidity in rheumatologic practice. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):362-5 (In Russ.). doi: 10.14412/1995-4484-2014-362-365
27. Османов ЭМ, Маньяков РР, Османов РЭ и др. Медицина 4 «п» как основа Osmanov EM, Man'yakov RR, Osmanov RE, et al. Medicine 4 «p» as the basis of a new healthcare system. Vestnik Rossiyskikh Universitetov. Matematika. 2017;(6-2). Available from: https://cyberleninka.ru/article/n/meditsina-4-p-kak-osnova-novoy-sistemy-zdravoohraneniya (In Russ.).
28. Nasonov EL. Rheumatoid arthritis: problems and significance of personalized medicine. Terapevticheskii Аrkhiv. 2012;84(5):5-9 (In Russ.).
29. Public analytical report on the scientific and technological direction «Biomedicine». Available from: https://reestr.extech.ru/docs/analytic/reports/medicine.pdf (In Russ.).
30. Dedov II, Tyul'pakov AN, Chekhonin VP, et al. Personalized medicine: current status and prospects. Vestnik Rossiyskoy Akademii Meditsinskikh Nauk. 2012;67(12):4-12 (In Russ.). doi: 10.15690/vramn.v67i12.474
31. Nasonov EL, Lila AM, Galushko EA, Amirdzhanova VN. Strategy for development of rheumatology: From scientific achievements to practical health-care. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):339-43 (In Russ.). doi: 10.14412/1995-4484-2017-339-343
32. Di Sanzo M, Cipolloni L, Borro M, et al. Clinical applications of personalized medicine: A new paradigm and challenge. Curr Pharm Biotechnol. 2017;18(3):194-203. doi: 10.2174/1389201018666170224105600
33. Ospelt C, Reedquist KA, Gay S, Tak PP. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? Autoimmun Rev. 2011 Jul;10(9):519-24. doi: 10.1016/j.autrev.2011.04.001
34. Wu H, Deng Y, Feng Y, et al. Epigenetic regulation in B-cell maturation and its dysregulation in autoimmunity. Cell Mol Immunol. 2018 Jul;15(7):676-84. doi: 10.1038/cmi.2017.133
35. Long H, Yin H, Wang L, et al. The critical role of epigenetics in systemic lupus erythematosus and autoimmunity. J Autoimmun. 2016 Nov;74:118-38. doi: 10.1016/j.jaut.2016.06.020
36. Kringelbach TM, Glintborg B, Hogdall EV, et al; Biomarker Protocol Study Group. Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study. BMJ Open. 2018;8(2):e019325. doi: 10.1136/bmjopen-2017-019325
37. Paik YK, Omenn GS, Hancock WS, et al. Advances in the Chromosome-Centric Human Proteome Project: looking to the future. Expert Rev Proteom. 2017 Dec;14(12):1059-71. doi: 10.1080/14789450.2017.1394189
38. Gupta L, Ahmed S, Jain A, Misra R. Emerging role of metabolomics in rheumatology. Int J Rheum Dis. 2018 Aug;21(8):1468-77. doi: 10.1111/1756-185X.13353
39. Han SW, Sa KH, Kim SI, et al. CCR5 gene polymorphism is a genetic risk factor for radiographic severity of rheumatoid arthritis. Tissue Antigens. 2012 Nov;80(5):416-23. doi: 10.1111/j.1399-0039.2012.01955.x
40. Santos MJ, Fernandes D, Capela S, et al. Interleukin-6 promoter polymorphism -174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients. Clin Rheumatol. 2011 Mar;30(3):409-13. doi: 10.1007/s10067-010-1640-y
41. Jönsson N, Erlandsson E, Gunnarsson L, et al. Monocyte chemoattractant protein-1 in antineutrophil cytoplasmic autoantibody-associated vasculitis: biomarker potential and association with polymorphisms in the MCP-1 and the CC chemokine receptor-2 gene. Mediat Inflamm. 2018 Mar 12;2018:6861257. doi: 10.1155/2018/6861257
42. Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014 Apr;77(4):704-14. doi: 10.1111/bcp.12226
43. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 Feb 19;360(8):753-64. doi: 10.1056/NEJMoa0809329
44. Hou Q, Li S, Li L, et al. Association between SLCO1B1 gene T521C polymorphism and statin-related myopathy risk: A metaanalysis of case-control studies. Medicine (Baltimore). 2015 Sep;94(37):e1268. doi: 10.1097/MD.0000000000001268
45. Gul B, Lansky A, Budoff MJ, et al. The clinical utility of a precision medicine blood test incorporating age, sex, and gene expression for evaluating women with stable symptoms suggestive of obstructive coronary artery disease: Analysis from the PRESET Registry. J Womens Health (Larchmt). 2019 May;28(5):728-35. doi: 10.1089/jwh.2018.7203
46. Tonner C, Schmajuk G, Yazdany J. A new era of quality measurement in rheumatology: electronic clinical quality measures and national registries. Curr Opin Rheumatol. 2017 Mar;29(2):131-7. doi: 10.1097/BOR.0000000000000364
47. Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472-84 (In Russ.). doi: 10.14412/1995-4484-2015-472-484
48. Aseeva EA, Dubikov AI, Levasheva LA, et al. The registry of systemic lupus erythematosus patients, a Eurasian cohort (RENAISSANCE). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):520-6 (In Russ.). doi: 10.14412/1995-4484-2016-520-526
49. Beketova TV. The value of the Russian National Registry of patients with ANCA-associated systemic vasculitis as an innovative tool of personalized induction and maintenance therapy. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(5):499-507 (In Russ.). doi: 10.14412/1995-4484-2016-499-507
50. Beketova T, Nasonov E. Rituximab for ANCA-associated vasculitis: one center experience of personalized treatment strategy. Rheumatology. 2019;58(2):285, kez063.009. doi: 10.1093/rheumatology/kez063.009
51. Kim KJ, Tagkopoulos I. Application of machine learning in rheumatic disease research. Korean J Intern Med. 2019;34(4):708-22. doi: 10.3904/kjim.2018.349
52. Ekins S, Puhl AC, Zorn KM, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019 May;18(5):435-41. doi: 10.1038
Review
For citations:
Beketova T.V. The development of rheumatology at the stage of formation of a new technological paradigm. Rheumatology Science and Practice. 2019;57(5):490-495. (In Russ.) https://doi.org/10.14412/1995-4484-2019-490-495
Views:
933
Email this article 